TITLE

Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model

PUB. DATE
January 2009
SOURCE
Radiation Oncology;2009, Vol. 4, p66
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
48165164

 

Related Articles

  • Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β. Jun Ohishi; Mikiko Aoki; Kazuki Nabeshima; Junji Suzumiya; Tamotsu Takeuchi; Akira Ogose; Michiyuki Hakozaki; Yuichi Yamashita; Hiroshi Iwasaki // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive and associated with poor prognosis. Basic research to develop new treatment regimens is critically needed. Methods: The effects of imatinib mesylate on MPNSTs were examined in six human MPNST cell lines and in a...

  • Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia? Chunduri, S.; Dobogai, L. C.; Bruno, A.; Kadkol, S.; Rondelli, D. // Leukemia (08876924);Mar2005, Vol. 19 Issue 3, p456 

    Presents a letter to the editor related to post-transplant treatment with imatinib mesylate.

  • The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. Seong-Wook Yun; Ertmer, Alexa; Flechsig, Eckhard; Gilch, Sabine; Riederer, Peter; Gerlach, Manfred; Schätzl, Hermann M.; Klein, Michael A. // Journal of NeuroVirology;Aug2007, Vol. 13 Issue 4, p328 

    Prion diseases are fatal neurodegenerative disorders with no effective therapy. A hallmark of prion disease is the conversion of the normal cellular form of prion protein PrPC into a disease-associated isoform PrPSc. The authors recently have shown that a tyrosine kinase inhibitor, imatinib...

  • Successful unrelated allogeneic stem cell transplantation after treatment of lymphoid blast crisis CML with imatinib and imatinib-containing conditioning regimen in a 16-year-old male. Koch, M; Lang, P; Bader, P; Kreyenberg, H; Schumm, M; Scheel-Walter, H; Hochhaus, A; Niethammer, D; Greil, J // Bone Marrow Transplantation;Sep2003, Vol. 32 Issue 5, p541 

    Reports on the case of a male patient diagnosed with lymphoid blast crisis chronic myeloid leukemia. Results of the treatment with imatinib mesylate; Analysis of cerebrospinal fluid; Efficacy of imatinib mesylate treatment to the patient.

  • FORMULATION AND EVALUATION OF MICROSPHERES BY CHEMICAL CROSSLINKING METHOD USING IMATINIB MESYLATE AS MODEL DRUG. Senthil, S. P.; Senthilkumar, K. L.; Sandu, Nagesh R.; Ezhilmuthu, R. P.; Saravanan, M. M. // International Journal of Pharmaceutical Sciences Review & Resear;Jul/Aug2012, Vol. 15 Issue 2, p46 

    The present research deals with formulation of microspheres containing an Anti-cancer drug Imatinib mesylate reduce the frequency of dosing. Imatinib mesylate is a protein-tyrosine kinase inhibitor, useful in the treatment of various types of cancer and used in the treatment of atherosclerosis,...

  • Effects of Imatinib Mesylate in Mouse Models of Multiple Sclerosis and In vitro Determinants. Azizi, Gholamreza; Haidari, Mohsen Reza; Khorramizadeh, Mohammadreza; Naddafi, Fatemeh; Sadria, Reza; Javanbakht, Mohammad Hassan; Sedaghat, Reza; Zavareh, Farzaneh Tofighi; Mirshafiey, Abbas // Iranian Journal of Allergy, Asthma & Immunology;Jun2014, Vol. 13 Issue 3, p198 

    Experimental autoimmune encephalomyelitis (EAE) is a mouse model for multiple sclerosis (MS), This autoimmune disease is mainly mediated by adaptive and innate immune responses that lead to an inflammatory demyelination and axonal damage. Imatinib mesylate is a selective protein tyrosine kinase...

  • Lichen planus associated with imatinib mesylate. Kaliyadan, Feroze; Ganesan, T. S. // Indian Journal of Dermatology, Venereology & Leprology;Sep/Oct2009, Vol. 75 Issue 5, p527 

    A letter to the editor is presented in response to an article about the treatment of lichen planus associated with imatinib mesylate which appeared in previous issue.

  • Imatinib.  // Reactions Weekly;8/10/2013, Issue 1465, p22 

    An abstract of the article "Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia," by M. Machaczka and colleagues is presented.

  • Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models. Gobin, Bérengère; Moriceau, Gatien; Ory, Benjamin; Charrier, Céline; Brion, Régis; Blanchard, Frederic; Redini, Françoise; Heymann, Dominique // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma), a...

  • Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours. Huse, Daniel M.; Von Mehren, Margaret; Lenhart, Gregory; Joensuu, Heikki; Blanke, Charles; Weiwei Feng; Finkelstein, Stan; Demetri, George // Clinical Drug Investigation;2007, Vol. 27 Issue 2, p85 

    BACKGROUND AND OBJECTIVE: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is partly dependent on reimbursement by third-party payers in many countries. The objective of this study...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics